Sofia Hamada Juca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sofia Hamada Juca has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Everton Cazzo
State University of Campinas, Campinas, Brazil
1 shared publication - Giulia Almiron da Rocha Soares
Universidade Metropolitana de Santos, Santos, Brazil
1 shared publication - Josélio Rodrigues de Oliveira-Filho
Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
1 shared publication - Pedro Bicudo Bregion
State University of Campinas, Campinas, Brazil
1 shared publication - Rafaela Hamada Juca
State University of Campinas, Campinas, Brazil
1 shared publication - Victor Kenzo Ivano
State University of Campinas, Campinas, Brazil
1 shared publication
Latest Publications
- 8 January 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (2) , 587-601
Comparative Analysis of Renal Function Outcomes Following Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Systematic Review and Meta-analysis
Background Obesity is a significant risk factor for chronic kidney disease (CKD), with metabolic bariatric surgery offering potential renal benefits. However, there is limited comparative data on the impact of Roux-en-Y gastric bypass (RYGB) versus laparoscopic sleeve gastrectomy (LSG) on renal function in individuals with obesity without end-stage renal disease (ESRD). The objective of this study was to compare renal function outcomes following RYGB and LSG in patients with obesity, focusing on estimated glomerular filtration rate (eGFR), serum creatinine, albumin-creatinine ratio (ACR), and serum cystatin C. Methods A systematic review and meta-analysis were conducted following Cochrane and PRISMA guidelines. Data from 17 observational studies (n = 3339) were analyzed. Primary outcomes included changes in eGFR, ACR, serum creatinine, and cystatin C. Secondary outcomes included excess weight loss (%EWL) and total weight loss (%TWL). Statistical analysis involved fixed and random-effects models based on heterogeneity levels. Results RYGB demonstrated significant improvements in eGFR (SMD = − 0.71; 95% CI − 0.89 to − 0.52, p < 0.00001) and serum cystatin C (MD = − 0.10; 95% CI − 0.17 to − 0.03, p = 0.004) compared to LSG. No significant differences were found for serum creatinine (MD = − 1.06; 95% CI − 4.42 to 2.30, p = 0.54) or ACR (MD = 1.95; 95% CI − 0.39 to 4.29, p = 0.10). RYGB also showed greater long-term weight loss, particularly at 5 years (%EWL: MD = 22.00; 95% CI 6.56 to 37.44, p = 0.005). Conclusions RYGB offers similar renal improvements with superior weight loss compared to LSG in individuals with obesity without ESRD. These findings emphasize the need for personalized treatment approaches and further research to validate these outcomes.
- 8 January 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (2) , 587-601
Comparative Analysis of Renal Function Outcomes Following Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Systematic Review and Meta-analysis
Background Obesity is a significant risk factor for chronic kidney disease (CKD), with metabolic bariatric surgery offering potential renal benefits. However, there is limited comparative data on the impact of Roux-en-Y gastric bypass (RYGB) versus laparoscopic sleeve gastrectomy (LSG) on renal function in individuals with obesity without end-stage renal disease (ESRD). The objective of this study was to compare renal function outcomes following RYGB and LSG in patients with obesity, focusing on estimated glomerular filtration rate (eGFR), serum creatinine, albumin-creatinine ratio (ACR), and serum cystatin C. Methods A systematic review and meta-analysis were conducted following Cochrane and PRISMA guidelines. Data from 17 observational studies (n = 3339) were analyzed. Primary outcomes included changes in eGFR, ACR, serum creatinine, and cystatin C. Secondary outcomes included excess weight loss (%EWL) and total weight loss (%TWL). Statistical analysis involved fixed and random-effects models based on heterogeneity levels. Results RYGB demonstrated significant improvements in eGFR (SMD = − 0.71; 95% CI − 0.89 to − 0.52, p < 0.00001) and serum cystatin C (MD = − 0.10; 95% CI − 0.17 to − 0.03, p = 0.004) compared to LSG. No significant differences were found for serum creatinine (MD = − 1.06; 95% CI − 4.42 to 2.30, p = 0.54) or ACR (MD = 1.95; 95% CI − 0.39 to 4.29, p = 0.10). RYGB also showed greater long-term weight loss, particularly at 5 years (%EWL: MD = 22.00; 95% CI 6.56 to 37.44, p = 0.005). Conclusions RYGB offers similar renal improvements with superior weight loss compared to LSG in individuals with obesity without ESRD. These findings emphasize the need for personalized treatment approaches and further research to validate these outcomes.